"Octreotide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.
| Descriptor ID |
D015282
|
| MeSH Number(s) |
D04.345.566.650 D12.644.641.650
|
| Concept/Terms |
SMS 201-995- SMS 201-995
- SMS 201 995
- SMS 201995
- SM 201-995
- SM 201 995
- SM 201995
- Sandoz 201-995
- Sandoz 201 995
- Sandoz 201995
- Compound 201-995
- Compound 201 995
- Compound 201995
- SAN 201-995
- SAN 201 995
- SAN 201995
|
Below are MeSH descriptors whose meaning is more general than "Octreotide".
Below are MeSH descriptors whose meaning is more specific than "Octreotide".
This graph shows the total number of publications written about "Octreotide" by people in this website by year, and whether "Octreotide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 6 | 5 | 11 |
| 2018 | 6 | 2 | 8 |
| 2019 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Octreotide" by people in Profiles.
-
68Ga-DOTATOC-avid lymphadenopathies induced from COVID-19 mRNA vaccination. Jpn J Clin Oncol. 2021 12 01; 51(12):1765.
-
Severe respiratory failure in a patient with COVID-19 and acromegaly: rapid improvement after adding octreotide. BMJ Case Rep. 2021 Aug 17; 14(8).
-
Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues. Oncologist. 2021 07; 26(7):e1171-e1178.
-
Acquired factor V inhibitor in the setting of coronavirus disease 2019 infection. Blood Coagul Fibrinolysis. 2021 Jun 01; 32(4):294-297.
-
A metastatic tumor is no different to a viral pandemic: lessons learnt from COVID-19 may teach us to change the PRRT paradigm. Eur J Nucl Med Mol Imaging. 2020 09; 47(10):2223-2226.
-
Endocrinology in the time of COVID-19: Management of pituitary tumours. Eur J Endocrinol. 2020 Jul; 183(1):G17-G23.
-
Effect of acute upper gastrointestinal bleeding manifestations at admission on the in-hospital outcomes of liver cirrhosis: hematemesis versus melena without hematemesis. Eur J Gastroenterol Hepatol. 2019 Nov; 31(11):1334-1341.
-
Pegvisomant Improves Glucose Metabolism in Acromegaly: A Meta-Analysis of Prospective Interventional Studies. J Clin Endocrinol Metab. 2019 07 01; 104(7):2892-2902.
-
Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. Endocrine. 2019 11; 66(2):417-424.
-
68Ga-DOTATOC PET/CT in Thyroid Metastases of Lung Carcinoid. Clin Nucl Med. 2018 Dec; 43(12):e492-e494.